Phase distribution of chronic myeloid leukemia in Bangladesh

Abstract

BackgroundHere, we report the phase distribution of chronic myeloid leukemia (CML), defined based on the World Health Organization criteria, among 63 patients in Bangladesh. All patients were diagnosed based on complete blood count, bone marrow examination including bone marrow aspiration and reverse-transcriptase polymerase chain reaction (RT-PCR). Out of 63 patients, 42 were male and 21 were female. The mean age of the subjects was 37.4 years, with an age range of 17-60 years. The majority of patients (86%) were classified in the chronic phase (CP), 7 (11%) in the accelerated phase (AP) and two (3%) in blast crisis (BC). The most frequent patient age ranges were 21-30 years for CP, 41-50 years for AP and 41-50 years for BC.ResultsThe Philadelphia chromosome was detected in 48 patients by RT-PCR. The mean total leukocyte counts, platelet counts, hemoglobin levels and marrow blast frequencies were 101 × 109/L, 409 × 109/L, 12.2 g/dl and 2.8% for CP; 121 × 109/L, 418 × 109/L, 8.7 g/dl and 15% for AP and 311 × 109/L, 396 × 109/L, 9.2 g/dl and 26% for BC, respectively.ConclusionThis study concluded that most CML patients in Bangladesh are from a younger age group (31-40 years). In addition, males were more commonly affected, although females were afflicted with this disease at a younger age.

Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data

“…However, because most CML patients (75%-86%) have been reported to be in the chronic phase, our study has captured the outcomes reflective of the general CML population. 43,44 Fifth, the patient's clinical response to TKI (eg, results from bone marrow biopsy and white blood cell counts) could not be measured in the database. Finally, the study period covered 2004 to 2010 and thus did not capture changes to the CML treatment patterns in recent years.…”

Management of chronic myeloid leukemia in blast crisis

“…This percentage varies between 0.9 and 6.7 % [1][2][3]. The largest survey on the incidence of BC at diagnosis of CML was published recently by the EUTOS population-based registry showing an incidence of 2.2 % in 2638 patients with newly diagnosed CML [4].…”

Normal platelet counts mask abnormal thrombopoiesis in patients with chronic myeloid leukemia

“…However, regulation of this process may be disrupted in certain diseases, particularly in neoplasms with a clonal origin (12,(18)(19)(20). It was hypothesized that dysmegakaryocytes reflect disorders of megakaryocyte development and result in dysregulated platelet production, as indicated by higher MPV, P-LCR and PDW values in patients with CML than in healthy controls.…”